BRD4 and ovarian carcinoma: reported that inhibiting SEs by BRD4 inhibitors JQ1 abrogates expression levels of ALDH1A1 and other stem‐related genes, followed by decreasing chemotherapy resistance and tumour relapse in ovarian cancer.